CorMedix, Inc. (CRMD)
8.61
+0.23
(+2.74%)
USD |
NASDAQ |
Sep 02, 16:00
8.54
-0.07
(-0.81%)
Pre-Market: 08:42
CorMedix Research and Development Expense (Annual) : 19.33M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 19.33M |
| December 31, 2024 | 3.942M |
| December 31, 2023 | 13.16M |
| December 31, 2022 | 10.68M |
| December 31, 2021 | 13.13M |
| December 31, 2020 | 13.38M |
| December 31, 2019 | 11.05M |
| December 31, 2018 | 18.82M |
| December 31, 2017 | 24.49M |
| Date | Value |
|---|---|
| December 31, 2016 | 15.74M |
| December 31, 2015 | 6.282M |
| December 31, 2014 | 1.319M |
| December 31, 2013 | 1.227M |
| December 31, 2012 | 1.188M |
| December 31, 2011 | 4.098M |
| December 31, 2010 | 5.494M |
| December 31, 2009 | 4.888M |
| December 31, 2008 | 3.083M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Innoviva, Inc. | 30.60M |
| Zevra Therapeutics, Inc. | 12.55M |
| Filana Therapeutics, Inc. | 26.59M |
| Eloxx Pharmaceuticals, Inc. | 3.056M |
| Cannabis Global, Inc. | -- |